Fertility Treatments Health Discussion Replies-Central Texas College .

Discussion7 Need 150 words response in own words, no references required Reply 1 As a manufacturer of Serophene or Pergonal, I would voluntarily release information regarding the findings related to the use of these fertility drugs and the increased risk of developing ovarian cancer. Past pieces of research have examined whether fertility treatments can raise risks of developing ovarian cancer. It is essential to note that such studies have yielded reassuring findings. The nature of these studies demanded welldesigned approaches in collecting data and making follow-ups in a bid to establish fertility treatment effects in the study populations depending on individual patient and cancer description (Diergaarde & Kurta, 2014). Substantive evidence indicates that the usage of fertility drugs by a majority of women does not substantially contribute to the development of cancer cells in the ovaries when focusing on predetermined confounding aspects. On the contrary, there still are many areas to examine, such as females with BRCA 1 and -2 mutations, those that remain nulligravid after using fertility drugs, long-term usage of fertility drugs, and the impact of such drugs on various subgroups (Diergaarde & Kurta, 2014). Moreover, other researches in this domain have reported that it is establishing a link between the risk of ovarian cancer and fertility drug use since a majority of females exposed to those treatments are now starting to reach the age range for ovarian cancer. In the corporate world, all manufacturers have to ensure the safety of people who use their drugs. Hiding crucial information, especially that which might lead to loss of human life, often results in loss of current and potential investors. As much as the revelation may lead to the realization of lower revenues for my company, leakage of such data through another party would be more devastative, attracting lawsuits. More studies must be covered to identify specific factors that contribute to ovarian cancer as a result of using fertility treatment. Given that there many of these factors to research as mentioned above, it is crucial to continue monitoring women who have already been exposed to the drugs but stop the manufacture of the same till significant findings are established. The safety of consumers is part of the corporate social responsibility as a manufacturer. References Diergaarde, B., & Kurta, M. (2014). Use of fertility drugs and risk of ovarian cancer. Current Opinion In Obstetrics And Gynecology, 26(3), 125-129. https://doi.org/10.1097/gco.0000000000000060 Reply-2 As a drug manufacturer, I would voluntarily release the information about the drugs on the package. The action would show transparency in our company. I understand that that action would scare away potential buyers. However, showing a slide could be a way of building the reputation of the company. Ovarian cancer has been caused by fertility drugs previously, meaning that many people are using the drugs and are at risk of contracting the dangerous disease (Kurta et al, 2014). It would, therefore, be ethical to raise awareness about drugs. Fertility drugs have been surprisingly found to cause infertility. The new study indicates that drugs expose users to contracting ovarian cancer. Numerous investigations were inspiring the statement that they didn’t approve a stable association amid ovarian cancer also the usage of fertility medications (Lindsay, Daniel, & Zain, 2017). People have been using drugs since BC and every drug is known to have a side effect but the probability of its cure for the disease is more observed as compared to its side effects. Side effects are on very little note depending on each and everyone’s body. This study hasn’t proven over too many people and the cases are rare but knowing facts to studies is a right of medicine for people. Companies have to comply with the set health policies from the state to be certified to comply with the environmental and human safety policies. Different state agencies are dedicated to ensuring healthy practice is encompassed in the production sector. World health organization has a set of policies that must be met by the producers and manufacturers to ensure the health of people consuming their products is guaranteed (Schwartz, 2013). The producers and manufacturers have to ensure the production process does not harm the environment nor the consumers of the products produced. References: Department of Health & Human Services. (2020, February 26). Medicine information leaflets for consumers. Retrieved June 18, 2020, https://www.betterhealth.vic.gov.au/health/conditionsandtreatments/medicine-information-leaflets-for-consumers